Coherus BioSciences (NASDAQ:CHRS) is a company that capitalizes on the stock market 1.1 billion dollars and operates in the United States in the biopharmaceutical sector and in the biosimilar and immuno-oncology sectors. Our Research Department believes that this Wall Street-listed stock should be watched as it could fivefold.
Now we are going to study the reasons but first let’s make a premise on the current short-term graphic situation of the American markets. In the month of April, two setups will expire (5/6 and 16) and around these dates a fast retracement could start / stop. As for our broader view, we see no dangers that a sustained downside could begin until the first week of August. From August 2021 until July / October 2022, American markets could give way to a bearish side phase.
We come to our main topic.
Coherus BioSciences stock closed the trading day of April 2 at a price of 14.55, down 0.41% from the previous session. Since the beginning of the year, it has marked the minimum at 14.02 and the maximum at 22.22.
What to wait from now on?
Summary budget analysis
Earnings are expected to grow 30.45% annually while they have grown 46.2% over the past year. The recommendations of the other analysts (9 reviews) estimate a fair value in the area of $ 27.89 per share. Our calculations instead estimate a fair value in the area of 80 dollars per share with a truly extraordinary undervaluation compared to the current price.
This Wall Street-listed stock should be kept an eye on as it could quintuple
Despite the strong estimated undervaluation, the short, medium and long-term trend is firmly bearish. Until there is a monthly close above 16.81, the decline could continue to 10.86 and then 8.32.
The operational strategy
This is a security to monitor but at the moment it should not be bought or accumulated. The advice is to wait on the sidelines waiting for graphic developments.
–
(We remind you to carefully read the warnings regarding this article, which can be consulted who”)
